Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 19/20 | 0.48 |
| ▸ | SCN5A | Q14524 | 14/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 12/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | GHSR | Q92847 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | VEGFA | P15692 | 1/20 | 0.34 |
| ▸ | FLT1 | P17948 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL840444 | 0.89 | SCN9A (0.57) | SCN9ASCN5AKCNH2SLC6A3GHSR | |
| SCHEMBL839851 | 0.88 | SCN9A (0.56) | SCN9ASCN5AKCNH2SLC6A3GHSR | |
| SCHEMBL839829 | 0.81 | SCN9A (0.52) | SCN9ASCN5AKCNH2SLC6A3GHSR | |
| SCHEMBL840300 | 0.80 | SCN9A (0.58) | SCN9ASCN5AKCNH2SLC6A3GHSR | |
| SCHEMBL840480 | 0.80 | SCN9A (0.46) | SCN9ASCN5AKCNH2SLC6A3GHSR | |
| SCHEMBL840898 | 0.80 | SCN9A (0.51) | SCN9ASCN5AKCNH2SLC6A3GHSR | |
| SCHEMBL840414 | 0.79 | SCN9A (0.45) | SCN9ASCN5AKCNH2SLC6A3GHSR | |
| SCHEMBL3670706 | 0.78 | SCN9A (0.66) | SCN9ASCN5AKCNH2SLC6A3GHSR | |
| SCHEMBL840369 | 0.77 | SCN9A (0.52) | SCN9ASCN5AKCNH2SLC6A3GHSR | |
| SCHEMBL841597 | 0.76 | SCN9A (0.58) | SCN9ASCN5AKCNH2SLC6A3GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143408-B2 | N-(8-heteroaryltetrahydronaphtalene-2yl) or N-(5-heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | claimed |
| US-20100137322-A1 | NOVEL N-(8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N-(5-HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | US | claimed |
| US-20120238579-A1 | New Compounds 806 | BESIDKI YEVGENI (SE) | 2012-09-20 | — | — | US | disclosed |
| US-8143408-B2 | N-(8-heteroaryltetrahydronaphtalene-2yl) or N-(5-heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-20100137322-A1 | NOVEL N-(8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N-(5-HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137322-A1 | NOVEL N-(8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N-(5-HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | OPRL1, OPRK1, OPRD1 | SCN9A 302/4885SCN5A 55/4885KCNH2 399/4885 |
| US-20120238579-A1 | New Compounds 806 | CYP2B6, CYP11B2, NDUFS6 | SCN9A 2285/4885SCN5A 380/4885KCNH2 2078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.